GSK submits multiple myeloma treatment for approval to the US regulator
Portfolio Pulse from
GSK has submitted an application to the FDA for the approval of Blenrep, a treatment for relapsed or refractory multiple myeloma. If approved, it could be used in combination with other drugs for patients who have undergone prior therapy.
November 25, 2024 | 8:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's application for Blenrep to treat multiple myeloma has been accepted by the FDA. Approval could enhance GSK's oncology portfolio and revenue.
The FDA's acceptance of GSK's application for Blenrep indicates a potential new revenue stream if approved. This could positively impact GSK's stock as it expands its oncology offerings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100